Childhood routine jabs pick up after COVID backslide: UN

Routine childhood vaccination rates are improving globally after a decline during the COVID-19 pandemic, but significant gaps remain, with millions of children still missing out on vaccines, particularly in low-income countries, according to the United Nations. While progress has been made, efforts to bridge the disparities in immunization coverage are necessary to protect children from preventable diseases.

Inquiry Into UK’s COVID-19 Response: Matt Hancock expresses profound apology for every death caused

Former UK Health Secretary Matt Hancock has apologised for each Covid-19 death and acknowledged the “colossal” failure in assuming the virus’s spread could not be halted at the UK Covid-19 Inquiry.

Cheap diabetes drug reduces risk of long COVID: study

A study conducted in the United States found that taking the diabetes drug metformin after testing positive for COVID-19 reduced the risk of developing long COVID by 40 per cent. The trial involved over 1,100 overweight or obese participants, with half receiving metformin and half receiving a placebo. The findings were considered significant in the fight against long COVID, a condition that affects approximately one in 10 individuals who have had COVID-19.

Singapore Prime Minister Lee Hsien Loong tests positive for COVID-19 again in ‘post COVID rebound’

Singapore’s Prime Minister Lee Hsien Loong has tested positive for COVID-19 for the second time in a “post COVID rebound” incident. Despite being still infectious, Mr Lee assured the risk of transmission is low. In light of his diagnosis, he has opted for self-isolation and has had to miss public engagements, including the consecration ceremony of Sri Thendayuthapani Temple.

Critics say treaty text in international accord by WHO member states on pandemic is ‘step backwards’

Observers warn of weakened efforts to ensure equitable access to medical products in negotiations for a new pandemic treaty. Critics express concern over revisions that water down language aimed at addressing the inequity in accessing vaccines and medical products during the COVID pandemic. Urgency grows to align positions before the looming threat of future pandemics.

Travel industry looks to Chinese tourists to cap post-COVID rebound

Industry leaders are predicting a global tourism revival this year, with the return of Chinese tourists playing a significant role. The desire to travel is at an all-time high, with leisure travel surpassing business travel. Chinese tourists, now free from COVID-19 restrictions, are expected to contribute to the boom, putting pressure on the travel industry. Hotel chains are experiencing a shift in travel habits, with a greater focus on leisure rather than business. The industry is working to meet the surge in demand and recover from the challenges of the past two years.

Global dividends hit first quarter record US$326.7 billion

Global dividends reached a record high of US$326.7 billion in the first quarter, driven by banks, oil giants, and automakers. Dividends grew by 12% compared to the same period in 2022, despite economic challenges. One-off special dividends amounted to US$28.8 billion, with Ford and Volkswagen contributing significantly. The report by Janus Henderson predicts companies will distribute US$1.6 trillion in dividends in 2023.

WHO chief hopes for ‘historic’ pandemic accord

The World Health Organization (WHO) chief emphasized the need for a historic agreement on global health security as negotiations for a new pandemic accord begin. The aim is to better equip the world to prevent and respond to future pandemics. The accord, expected to be reached by May 2024, would mark a paradigm shift and recognize the interconnectedness of nations in addressing global health threats. The devastating impact of the COVID-19 pandemic serves as a reminder of the importance of a collective response and the lessons learned.

US becomes first country to approve Respiratory Syncytial Virus (RSV) vaccine

The US has approved the world’s first vaccine for Respiratory Syncytial Virus (RSV), with drugmaker GSK’s Arexvy being green-lighted for adults aged 60 and older. RSV is a common virus that can be serious for infants, the elderly, and those with weak immune systems. Other vaccine makers, including Pfizer and Moderna, are expected to follow soon. Rates of RSV and flu fell during COVID-19 lockdowns, but surged when restrictions were lifted, with young children hit hard.

Elderly COVID-19 patient dies from anaphylaxis, allegedly caused by Lianhua Qingwen

SINGAPORE — A 61-year-old elderly COVID-19 patient reportedly suffered from a life-threatening…